Differences in CD33 intensity between various myeloid neoplasms

Iman Jilani, Elihu Estey, Yang Huh, Youngson Joe, Taghi Manshouri, Marwan Yared, Francis Giles, Hagop Kantarjian, Jorge Cortes, Deborah Thomas, Michael Keating, Emil Freireich, Maher Albitar

Research output: Contribution to journalArticle

Abstract

We measured the concentration of CD33 antigen on the surface of cells in 315 bone marrow (BM) samples and 114 corresponding peripheral blood (PB) samples from patients with various leukemias (acute myeloid leukemia [AML], chronic myelogenous leukemia [CML], myeloproliferative disorder [MPD] other than CML, myelodysplastic syndrome [MDS]) and from control subjects. Overall CD33 intensity in total CD33+ cells was significantly higher in BM than in PB. CD33 intensity in total BM CD33+ cells differed significantly with the type of disease. The median number of CD33 molecules per cell was highest in AML, followed by MDS, CML, and control subjects and lowest in MPD. When only CD34+/CD33+ cells were examined, CD33 molecules per cell were highest in CD34+ cells in AML and lowest in MPD (P = .027). Patients with AML or MDS younger than 60 years had significantly higher intensity of CD33 expression on CD34+ cells than patients 60 years or older. Levels of CD33 intensity did not correlate with cytogenetics in patients with AML or MDS. There was no correlation between CD33 intensity and response to therapy or overall survival in 35 patients treated with protocols including Mylotarg. These data demonstrate variation in CD33 intensity between various leukemias.

Original languageEnglish (US)
Pages (from-to)560-566
Number of pages7
JournalAmerican Journal of Clinical Pathology
Volume118
Issue number4
DOIs
StatePublished - Oct 1 2002
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Myelodysplastic Syndromes
Myeloproliferative Disorders
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms
Sialic Acid Binding Ig-like Lectin 3
Leukemia
Bone Marrow
Cytogenetics
Bone Marrow Cells
Survival
Therapeutics

Keywords

  • Acute myeloid leukemia
  • CD33 intensity
  • Chronic myelogenous leukemia
  • Gemtuzumab ozogamicin
  • Monoclonal antibody therapy
  • Myelodysplastic syndrome
  • Myeloproliferative disorder
  • Mylotarg
  • Quantitative flow cytometry

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Jilani, I., Estey, E., Huh, Y., Joe, Y., Manshouri, T., Yared, M., ... Albitar, M. (2002). Differences in CD33 intensity between various myeloid neoplasms. American Journal of Clinical Pathology, 118(4), 560-566. https://doi.org/10.1309/1WMW-CMXX-4WN4-T55U

Differences in CD33 intensity between various myeloid neoplasms. / Jilani, Iman; Estey, Elihu; Huh, Yang; Joe, Youngson; Manshouri, Taghi; Yared, Marwan; Giles, Francis; Kantarjian, Hagop; Cortes, Jorge; Thomas, Deborah; Keating, Michael; Freireich, Emil; Albitar, Maher.

In: American Journal of Clinical Pathology, Vol. 118, No. 4, 01.10.2002, p. 560-566.

Research output: Contribution to journalArticle

Jilani, I, Estey, E, Huh, Y, Joe, Y, Manshouri, T, Yared, M, Giles, F, Kantarjian, H, Cortes, J, Thomas, D, Keating, M, Freireich, E & Albitar, M 2002, 'Differences in CD33 intensity between various myeloid neoplasms', American Journal of Clinical Pathology, vol. 118, no. 4, pp. 560-566. https://doi.org/10.1309/1WMW-CMXX-4WN4-T55U
Jilani, Iman ; Estey, Elihu ; Huh, Yang ; Joe, Youngson ; Manshouri, Taghi ; Yared, Marwan ; Giles, Francis ; Kantarjian, Hagop ; Cortes, Jorge ; Thomas, Deborah ; Keating, Michael ; Freireich, Emil ; Albitar, Maher. / Differences in CD33 intensity between various myeloid neoplasms. In: American Journal of Clinical Pathology. 2002 ; Vol. 118, No. 4. pp. 560-566.
@article{89e50fec224f4d71800e35d1012db182,
title = "Differences in CD33 intensity between various myeloid neoplasms",
abstract = "We measured the concentration of CD33 antigen on the surface of cells in 315 bone marrow (BM) samples and 114 corresponding peripheral blood (PB) samples from patients with various leukemias (acute myeloid leukemia [AML], chronic myelogenous leukemia [CML], myeloproliferative disorder [MPD] other than CML, myelodysplastic syndrome [MDS]) and from control subjects. Overall CD33 intensity in total CD33+ cells was significantly higher in BM than in PB. CD33 intensity in total BM CD33+ cells differed significantly with the type of disease. The median number of CD33 molecules per cell was highest in AML, followed by MDS, CML, and control subjects and lowest in MPD. When only CD34+/CD33+ cells were examined, CD33 molecules per cell were highest in CD34+ cells in AML and lowest in MPD (P = .027). Patients with AML or MDS younger than 60 years had significantly higher intensity of CD33 expression on CD34+ cells than patients 60 years or older. Levels of CD33 intensity did not correlate with cytogenetics in patients with AML or MDS. There was no correlation between CD33 intensity and response to therapy or overall survival in 35 patients treated with protocols including Mylotarg. These data demonstrate variation in CD33 intensity between various leukemias.",
keywords = "Acute myeloid leukemia, CD33 intensity, Chronic myelogenous leukemia, Gemtuzumab ozogamicin, Monoclonal antibody therapy, Myelodysplastic syndrome, Myeloproliferative disorder, Mylotarg, Quantitative flow cytometry",
author = "Iman Jilani and Elihu Estey and Yang Huh and Youngson Joe and Taghi Manshouri and Marwan Yared and Francis Giles and Hagop Kantarjian and Jorge Cortes and Deborah Thomas and Michael Keating and Emil Freireich and Maher Albitar",
year = "2002",
month = "10",
day = "1",
doi = "10.1309/1WMW-CMXX-4WN4-T55U",
language = "English (US)",
volume = "118",
pages = "560--566",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "4",

}

TY - JOUR

T1 - Differences in CD33 intensity between various myeloid neoplasms

AU - Jilani, Iman

AU - Estey, Elihu

AU - Huh, Yang

AU - Joe, Youngson

AU - Manshouri, Taghi

AU - Yared, Marwan

AU - Giles, Francis

AU - Kantarjian, Hagop

AU - Cortes, Jorge

AU - Thomas, Deborah

AU - Keating, Michael

AU - Freireich, Emil

AU - Albitar, Maher

PY - 2002/10/1

Y1 - 2002/10/1

N2 - We measured the concentration of CD33 antigen on the surface of cells in 315 bone marrow (BM) samples and 114 corresponding peripheral blood (PB) samples from patients with various leukemias (acute myeloid leukemia [AML], chronic myelogenous leukemia [CML], myeloproliferative disorder [MPD] other than CML, myelodysplastic syndrome [MDS]) and from control subjects. Overall CD33 intensity in total CD33+ cells was significantly higher in BM than in PB. CD33 intensity in total BM CD33+ cells differed significantly with the type of disease. The median number of CD33 molecules per cell was highest in AML, followed by MDS, CML, and control subjects and lowest in MPD. When only CD34+/CD33+ cells were examined, CD33 molecules per cell were highest in CD34+ cells in AML and lowest in MPD (P = .027). Patients with AML or MDS younger than 60 years had significantly higher intensity of CD33 expression on CD34+ cells than patients 60 years or older. Levels of CD33 intensity did not correlate with cytogenetics in patients with AML or MDS. There was no correlation between CD33 intensity and response to therapy or overall survival in 35 patients treated with protocols including Mylotarg. These data demonstrate variation in CD33 intensity between various leukemias.

AB - We measured the concentration of CD33 antigen on the surface of cells in 315 bone marrow (BM) samples and 114 corresponding peripheral blood (PB) samples from patients with various leukemias (acute myeloid leukemia [AML], chronic myelogenous leukemia [CML], myeloproliferative disorder [MPD] other than CML, myelodysplastic syndrome [MDS]) and from control subjects. Overall CD33 intensity in total CD33+ cells was significantly higher in BM than in PB. CD33 intensity in total BM CD33+ cells differed significantly with the type of disease. The median number of CD33 molecules per cell was highest in AML, followed by MDS, CML, and control subjects and lowest in MPD. When only CD34+/CD33+ cells were examined, CD33 molecules per cell were highest in CD34+ cells in AML and lowest in MPD (P = .027). Patients with AML or MDS younger than 60 years had significantly higher intensity of CD33 expression on CD34+ cells than patients 60 years or older. Levels of CD33 intensity did not correlate with cytogenetics in patients with AML or MDS. There was no correlation between CD33 intensity and response to therapy or overall survival in 35 patients treated with protocols including Mylotarg. These data demonstrate variation in CD33 intensity between various leukemias.

KW - Acute myeloid leukemia

KW - CD33 intensity

KW - Chronic myelogenous leukemia

KW - Gemtuzumab ozogamicin

KW - Monoclonal antibody therapy

KW - Myelodysplastic syndrome

KW - Myeloproliferative disorder

KW - Mylotarg

KW - Quantitative flow cytometry

UR - http://www.scopus.com/inward/record.url?scp=18244428964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244428964&partnerID=8YFLogxK

U2 - 10.1309/1WMW-CMXX-4WN4-T55U

DO - 10.1309/1WMW-CMXX-4WN4-T55U

M3 - Article

C2 - 12375643

AN - SCOPUS:18244428964

VL - 118

SP - 560

EP - 566

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 4

ER -